What share options in Autolus Therapeutics (AUTL) does Cynthia M. Butitta report on her Form 3?

She reports several "Share Option (right to buy)" positions over American Depositary Shares. These options have exercise prices between $2.38 and $30.24, with expiration dates running from 2028 through 2035, reflecting long-dated equity incentives.

Are Cynthia M. Butitta’s Autolus Therapeutics (AUTL) share options fully vested?

Some of the reported options are fully vested and exercisable. A footnote states that one option grant is fully vested, while another vests in twelve equal monthly installments commencing on July 26, 2025, indicating a mix of vested and vesting awards.

Autolus director Cynthia Butitta files Form 3

Autolus Therapeutics plc director Cynthia M. Butitta filed an initial ownership report showing her equity position in the company.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Autolus Therapeutics plc director Cynthia M. Butitta filed an initial ownership report showing her equity position in the company. She directly holds 10,000 American Depositary Shares, each convertible into one Ordinary Share, and a series of share options over additional American Depositary Shares with exercise prices ranging from $2.38 to $30.24 and expirations extending through 2035.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider BUTITTA CYNTHIA M

Role Director

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: American Depositary Shares — 10,000 contracts (Direct); Share Option (right to buy) — 382,095 contracts (Direct)

Footnotes (3)

F1. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
F2. Fully vested and exercisable.
F3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filed for Autolus Therapeutics (AUTL) by Cynthia M. Butitta show?

The Form 3 shows Cynthia M. Butitta’s initial ownership in Autolus Therapeutics. She reports holding 10,000 American Depositary Shares and multiple share option grants over additional ADSs, establishing her starting equity position as a director of the company.

How many Autolus Therapeutics (AUTL) American Depositary Shares does Cynthia M. Butitta directly own?

Cynthia M. Butitta directly owns 10,000 American Depositary Shares of Autolus Therapeutics. Each American Depositary Share is convertible at any time at her option into one Ordinary Share, according to the footnotes included with the ownership disclosure.

Does the Autolus Therapeutics (AUTL) Form 3 indicate recent buying or selling by Cynthia M. Butitta?

The disclosure reflects holdings rather than recent buying or selling activity. The entries are categorized as holdings with no buy or sell transaction codes, indicating an initial statement of beneficial ownership instead of a new market transaction.

What is the significance of the exercise prices on Cynthia M. Butitta’s Autolus Therapeutics (AUTL) options?

The exercise prices define the cost to acquire Autolus American Depositary Shares under each option. They range from $2.38 to $30.24 per share, and combined with long-dated expirations, they outline the potential future equity she can purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 08:01 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BUTITTA CYNTHIA M

(Last)

(First)

(Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON

W12 7FP

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	⁽¹⁾	⁽¹⁾	Ordinary Shares	10,000	⁽¹⁾	D
Share Option (right to buy)	⁽²⁾	03/08/2028	American Depositary Shares	47,095	$8.38	D
Share Option (right to buy)	⁽²⁾	03/28/2029	American Depositary Shares	25,000	$30.24	D
Share Option (right to buy)	⁽²⁾	06/18/2030	American Depositary Shares	12,500	$13.25	D
Share Option (right to buy)	⁽²⁾	06/18/2031	American Depositary Shares	12,500	$7.57	D
Share Option (right to buy)	⁽²⁾	06/28/2032	American Depositary Shares	20,000	$2.84	D
Share Option (right to buy)	⁽²⁾	06/30/2033	American Depositary Shares	105,000	$2.38	D
Share Option (right to buy)	⁽²⁾	06/28/2034	American Depositary Shares	80,000	$3.48	D
Share Option (right to buy)	⁽³⁾	06/26/2035	American Depositary Shares	80,000	$2.32	D

Explanation of Responses:

1. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

2. Fully vested and exercisable.

3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

	/s/ Cynthia Butitta	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR